Bibliographic record
Abstract
It is an honour and privilege to be the inaugural Editor-in-Chief (EIC) of the new journal Neuro-Oncology Advances (NOA). Neuro-Oncology Advances is the first open-access journal that is also an official journal of the Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO). The creation of this new journal has been a team sport, and culmination of hours of dedication and planning by various stakeholders. I am fortunate to be joined by a team of executive and associate Editors who bring the necessary experience and expertise to shape the path for this new journal. Amongst the many individuals, a few deserve special recognition, including the past president of SNO, Nino Chiocca, current president and former Editor-in-Chief of Neuro-Oncology Patrick Wen, together with current-EIC of Neuro-oncology, Ken Aldape, all of whom have been instrumental in making the vision for this new journal a reality. The journal is also a true partnership with EANO, represented by the past and current presidents, Wolfgang Wick and Martin van den Bent. Chas Haynes has with precise attention to details ensured a smooth execution in partnership with Oxford University Press. Neuro-Oncology Advances was conceptualized to meet an area of unmet need and work seamlessly with Neuro-Oncology to complement the vision, mandate and above all quality of the content material published. The field of neuro-oncology has experienced a tremendous growth in the past decade, with increasing interest in research and clinical care delivery for patients with brain tumours. There is a clear exponential rise in membership to the field and expertise being built throughout disciplines to advance neuro-oncology. Equally, the Neuro-Oncology has benefitted from this growth together with leadership to reach record high submissions and most importantly an impact factor that is competitive with reputable journals in the broader area of cancer research at 9.38. We are witnessing a transformation of the field of neuro-oncology; therefore it is timely to introduce an open-access journal. NOA will ensure that research and discoveries in the field is retained within the broader readership and community of the neuro-oncology field. NOA will serve to disseminate and raise awareness of the sound and competitive investigative work that is being done in the field that complements and advances the scope of Neuro-Oncology. NOA allows a mechanism to increase presence in areas of CNS oncology that are outside of the traditionally accepted mandates of Neuro-Oncology. NOA will commit to publications in the area of brain metastasis, as this is an area with a fast-pace changing landscape of treatment paradigms that demands a multi-disciplinary focus and recognition of the importance in advances. NOA will also include primary CNS treatment and the associated neurological complications and side effects of brain metastases. Similarly, there is a large momentum being built around research in meningiomas and other non-malignant tumours. NOA will place a stronger emphasis on non-malignant brain tumours, such as meningiomas, schwannomas, pituitary tumours, spinal and peripheral nerve tumours and many others that have traditionally not been included in the main mandate of Neuro-Oncology. Additionally, NOA will promote technological advances and innovation in surgery, radiation therapy delivery and neuro-imaging. NOA is an official partnership between SNO and EANO, where the leadership and direction is set jointly by the two societies. I am grateful to the support and recognition that Wolfgang Wick, as the deputy and executive editor representing EANO, will bring to the journal. I hope that NOA will become an invaluable resource for the field, that the readership and scientific community will endorse and patients will find useful. Furthermore, I hope that the excitement that I, the executive team and associate editors share for this journal will be adopted by you, to encourage submission of your work for publication.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.009 | 0.035 |
| Meta-epidemiology (narrow) | 0.004 | 0.002 |
| Meta-epidemiology (broad) | 0.005 | 0.003 |
| Bibliometrics | 0.007 | 0.002 |
| Science and technology studies | 0.004 | 0.003 |
| Scholarly communication | 0.013 | 0.007 |
| Open science | 0.004 | 0.003 |
| Research integrity | 0.021 | 0.025 |
| Insufficient payload (model declined to judge) | 0.030 | 0.024 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".